Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX and Enrolls First Patients in Clinical Trial

publication date: Aug 4, 2010
 | 
author/source: b3c newswire

Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEXTM (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

"For Glycotope, the approval of CetuGEXTM, our second antibody in the clinic, represents another important milestone," says Steffen Goletz, CEO & CSO of Glycotope. "CetuGEXTM is our first in a series of next generation biotherapeutic products. We expect that the strong advantages in various product aspects we have seen in preclinical studies will manifest in a clear clinical superiority compared to the currently marketed product. In addition, the second cell line of Glycotope´s glycooptimization platform GlycoExpressTM based on human cell lines has now been approved, meeting our ambitions for quality and speed." CetuGEXTM was the second antibody in clinical stage produced in Glycotope´s own GMP facility in Heidelberg.

About CetuGEXTM
CetuGEXTM is an improved version of a currently marketed anti-EGFR antibody which has been approved for the treatment of colorectal and head & neck cancers. The antibody's fully human glycosylation is optimized to yield a largely improved anti-tumor ADCC activity, bioavailability and contains no non-human immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. This was achieved with Glycotope´s proprietary technology platform GlycoExpressTM, a screening and high yield production system of glycoengineered human cell lines.

About Glycotope GmbH - www.glycotope.com
GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant carbohydrate structures known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpressTM, one of the company's proprietary technologies, allows making existing and new biopharmaceutical drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all steps from lead discovery, preclinical development, GMP production and clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEXTM) and significantly improved versions of antibodies as well as other marketed therapeutic proteins.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events